12 10, 2020

MHRA (GxP) Inspections during COVID19

By |2021-10-13T14:21:00+00:00October 12th, 2020|General News|

The COVID19 pandemic presents an unprecedented challenge to healthcare, the pharmaceutical industry’s supply chain and personnel movement. MHRA understands the impact of its work on industry, NHS and patients. This is not just in terms of our regulatory support to bring new technologies and products quickly and safely to market, but also the personnel and

5 10, 2020

Regulations for Pharmaceuticals Post Brexit

By |2021-10-13T14:30:17+00:00October 5th, 2020|General News|

The European Commission has published a Communication to prepare for the end of the transition period. The document is appropriately entitled "Getting ready for changes - Communication on readiness at the end of the transition period between the European Union and the United Kingdom". Far-reaching changes and consequences are therefore to be expected after 1

30 09, 2020

Complying with new GDP requirements

By |2021-10-13T14:27:04+00:00September 30th, 2020|General News|

In an ever changing and complex industry the role of the Responsible Person has developed and grown over the past 10 years as the focus of regulatory bodies have placed a higher level of scrutiny on how GDP principals are implemented and applied for Wholesale Distributors. Initially the main areas of compliance for

29 09, 2020

QP Responsibilities

By |2021-10-13T14:27:36+00:00September 29th, 2020|General News|

MIAS Pharma provides QP services for commercial and investigational medicinal products. Our QPs have experience in oversight and release of multiple types of products. Each type of product has it's own specific properties and challenges, which determines what approach should be taken to provide the best solutions. Sterile products have to be free

21 09, 2020

Pharma Industry Awards 2020

By |2021-10-14T10:17:33+00:00September 21st, 2020|General News|

We’re pleased to announce that MIAS Pharma Ltd has been shortlisted for Pharma Supplier of the Year in this years Pharma Industry awards. We look forward to a great evening and catching up with our peers and suppliers.Since launching in 2014, the Pharma Industry Awards has established itself as the benchmark for those demonstrating excellence in the pharma

24 09, 2019

Good Distribution Practice (GDP): Issue of Theft

By |2019-09-24T14:56:53+00:00September 24th, 2019|General News|

The wholesale distribution of medicinal products and active substances is an important activity. The quality and the integrity of medicinal products can be affected by a lack of adequate control. The quality, safety and efficacy of medicinal products depend on a whole range of different factors. The most important factors are that

19 08, 2019

Safety is top concern for recent U.S. drug importation proposal

By |2021-10-13T14:37:18+00:00August 19th, 2019|General News|

Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan”. The action plan would allow importation of certain prescription drugs from Canada and other countries. Importing drugs, whether from Canada or elsewhere in the world, poses a big

19 08, 2019

Safety is top concern for recent U.S. drug importation proposal

By |2021-10-13T14:36:55+00:00August 19th, 2019|General News|

Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan”. The action plan would allow importation of certain prescription drugs from Canada and other countries. Importing drugs, whether from Canada or elsewhere in the world, poses a big

15 08, 2019

What is considered GMP-compliant equipment design?

By |2019-08-15T10:11:08+00:00August 15th, 2019|General News|

A question that gets frequently asked is what GMP-compliant equipment design is or how a system has to be made up in order to be GMP compliant and suitable for the manufacturing of medicinal products / APIs. The short answer is: the system must be qualifiable. Since this require some clarification, here

11 07, 2019

Canada’s Cannabis Products: New Regulatory Approach

By |2019-07-11T11:10:55+00:00July 11th, 2019|General News|

Health Canada has proposed a regulatory pathway for a new class of cannabis products known as Cannabis Health Products (CHPs). On June 19, 2019, Health Canada started a consultation on potential market for CHPs that would not require a practitioner’s oversight. Health Canada are accepting comments until September 3, 2019. There is

Go to Top